{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:52:24Z","timestamp":1793019144253,"version":"4.5.0"},"reference-count":210,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101052444"],"award-info":[{"award-number":["101052444"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2021-ADG"],"award-info":[{"award-number":["ERC-2021-ADG"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004795","name":"Institut Universitaire de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015545","name":"Seerave Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["825410"],"award-info":[{"award-number":["825410"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE44\\u20130030"],"award-info":[{"award-number":["ANR-23-CE44\\u20130030"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-R4HC-0006 Ener-LIGHT"],"award-info":[{"award-number":["ANR-23-R4HC-0006 Ener-LIGHT"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE14\\u20130066"],"award-info":[{"award-number":["ANR-22-CE14\\u20130066"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["21-ESRE-0028"],"award-info":[{"award-number":["21-ESRE-0028"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021716","name":"Universit\u00e9 de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007391","name":"Association pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006431","name":"Canc\u00e9rop\u00f4le Ile de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","award":["ANR-23-RHUS-0010"],"award-info":[{"award-number":["ANR-23-RHUS-0010"]}],"id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","award":["PAIR-Ob\\u00E9sit\\u00E9 INCa_1873"],"award-info":[{"award-number":["PAIR-Ob\\u00E9sit\\u00E9 INCa_1873"]}],"id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","award":["ANR-21-RHUS-0017"],"award-info":[{"award-number":["ANR-21-RHUS-0017"]}],"id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["INCa_18542"],"award-info":[{"award-number":["INCa_18542"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016784","name":"Equipex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004100","name":"Labex","doi-asserted-by":"publisher","award":["ANR-18-IDEX-0001"],"award-info":[{"award-number":["ANR-18-IDEX-0001"]}],"id":[{"id":"10.13039\/501100004100","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.smim.2025.101996","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:26:25Z","timestamp":1759217185000},"page":"101996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Latest insights into oncolytic viro-immunotherapy with vesicular stomatitis virus"],"prefix":"10.1016","volume":"80","author":[{"given":"Manuela","family":"Lizarralde-Guerrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olagnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Maiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-7562","authenticated-orcid":false,"given":"Jonathan G.","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2025.101996_bib1","series-title":"Adv. Virus Res.","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/B978-0-12-800172-1.00005-7","article-title":"Arboviruses pathogenic for domestic and wild animals","author":"Hub\u00e1lek","year":"2014"},{"key":"10.1016\/j.smim.2025.101996_bib2","unstructured":"USDA APHIS | Vesicular Stomatitis, (n.d.). \u3008https:\/\/www.aphis.usda.gov\/aphis\/ourfocus\/animalhealth\/animal-disease-information\/cattle-disease-information\/vesicular-stomatitis-info\u3009 (accessed March 27, 2023)."},{"key":"10.1016\/j.smim.2025.101996_bib4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/pathogens10091092","article-title":"Vesicular stomatitis virus: from agricultural pathogen to vaccine vector","volume":"10","author":"Liu","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.smim.2025.101996_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0168-1702(02)00026-6","article-title":"Emergence and re-emergence of vesicular stomatitis in the United States","volume":"85","author":"Rodr\u00edguez","year":"2002","journal-title":"Virus Res."},{"key":"10.1016\/j.smim.2025.101996_bib6","unstructured":"N. Karabatsos, International catalogue of arboviruses, including certain other viruses of vertebrates, 3rd ed, American Society of Tropical Medicine and Hygiene for the Subcommittee on Information Exchange of the American Committee on Arthropod-borne Viruses, San Antonio, Tex., 1985."},{"key":"10.1016\/j.smim.2025.101996_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM196711092771901","article-title":"Human infection with the virus of vesicular stomatitis during an epizootic","volume":"277","author":"Fields","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.101996_bib8","series-title":"Encycl. Virol","first-page":"291","article-title":"Vesicular stomatitis virus","author":"Whelan","year":"2008"},{"key":"10.1016\/j.smim.2025.101996_bib9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1749-6632.1998.tb10655.x","article-title":"Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain","volume":"855","author":"Reiss","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.smim.2025.101996_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2006.10.026","article-title":"Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates","volume":"360","author":"Johnson","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.smim.2025.101996_bib11","unstructured":"Vesicular stomatitis Indiana virus, complete genome, (2018). \u3008http:\/\/www.ncbi.nlm.nih.gov\/nuccore\/NC_001560.1\u3009 (accessed March 24, 2023)."},{"key":"10.1016\/j.smim.2025.101996_bib12","series-title":"Rabies Second Ed.","first-page":"23","article-title":"2 - rabies virus","author":"Wunner","year":"2007"},{"key":"10.1016\/j.smim.2025.101996_bib13","article-title":"Viral genome size distribution does not correlate with the antiquity of the host lineages","volume":"3","author":"Campillo","year":"2015","journal-title":"Front. Ecol. Evol."},{"key":"10.1016\/j.smim.2025.101996_bib14","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1038\/s41467-022-33664-4","article-title":"Atomic model of vesicular stomatitis virus and mechanism of assembly","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib15","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2025.101996_bib16","unstructured":"The LDL Receptor | Arteriosclerosis, Thrombosis, and Vascular Biology, (n.d.). \u3008https:\/\/www.ahajournals.org\/doi\/10.1161\/ATVBAHA.108.179564\u3009 (accessed April 8, 2024)."},{"key":"10.1016\/j.smim.2025.101996_bib17","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.chembiol.2010.10.009","article-title":"Activation of LDL receptor (LDLR) expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter","volume":"17","author":"Matsui","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.smim.2025.101996_bib18","doi-asserted-by":"crossref","first-page":"a016972","DOI":"10.1101\/cshperspect.a016972","article-title":"Endocytosis of viruses and bacteria","volume":"6","author":"Cossart","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.smim.2025.101996_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0022-2836(82)90269-8","article-title":"Pathway of vesicular stomatitis virus entry leading to infection","volume":"156","author":"Matlin","year":"1982","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.smim.2025.101996_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/fvl.09.72","article-title":"Internalization and fusion mechanism of vesicular stomatitis virus and related rhabdoviruses","volume":"5","author":"Sun","year":"2010","journal-title":"Future Virol."},{"key":"10.1016\/j.smim.2025.101996_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000394","article-title":"Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization","volume":"5","author":"Cureton","year":"2009","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.smim.2025.101996_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/v4010117","article-title":"Molecular and cellular aspects of rhabdovirus entry","volume":"4","author":"Albertini","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2025.101996_bib23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/viro.1999.0120","article-title":"Expression of human immunodeficiency virus type 1 gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope","volume":"268","author":"Haglund","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.smim.2025.101996_bib24","unstructured":"D. Lyles, I. Kuzmin, C. Rupprecht, Rhabdoviridae, in: 2013: pp. 885\u2013922."},{"key":"10.1016\/j.smim.2025.101996_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-66942-6","article-title":"Vesicular stomatitis virus nucleocapsids diffuse through cytoplasm by hopping from trap to trap in random directions","volume":"10","author":"Holzwarth","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2025.101996_bib26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00253-024-13078-6","article-title":"Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration","volume":"108","author":"G\u00f6bel","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.smim.2025.101996_bib27","first-page":"3268","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.smim.2025.101996_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jbiotec.2018.11.023","article-title":"Optimization of production of vesicular stomatitis virus (VSV) in suspension serum-free culture medium at high cell density","volume":"289","author":"Elahi","year":"2019","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.smim.2025.101996_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2010.159","article-title":"Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment","volume":"22","author":"Ausubel","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.smim.2025.101996_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.992069","article-title":"Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP","volume":"10","author":"Gautam","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.smim.2025.101996_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/biotech10040022","article-title":"Highly efficient purification of recombinant VSV-\u2206G-Spike vaccine against SARS-CoV-2 by Flow-Through chromatography","volume":"10","author":"Lerer","year":"2021","journal-title":"Biotech"},{"key":"10.1016\/j.smim.2025.101996_bib33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.101996_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.virol.2018.06.018","article-title":"Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors","volume":"522","author":"Zhang","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.smim.2025.101996_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1085940","article-title":"Preclinical efficacy of oncolytic VSV-IFN\u03b2 in treating cancer: a systematic review","volume":"14","author":"Moglan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib36","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41596-024-00985-1","article-title":"Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy","volume":"19","author":"Gujar","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.smim.2025.101996_bib37","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2010.103","article-title":"Identification of genetically modified maraba virus as an oncolytic rhabdovirus","volume":"18","author":"Brun","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009443","article-title":"Combination of oncolytic maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling","volume":"12","author":"Armstrong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib39","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.omto.2020.10.007","article-title":"Oncolytic rhabdovirus vaccine boosts chimeric Anti-DEC205 priming for effective cancer immunotherapy","volume":"19","author":"Tzelepis","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4939-9794-7_19","article-title":"Considerations for clinical translation of MG1 maraba virus","volume":"2058","author":"Breitbach","year":"2020","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"10.1016\/j.smim.2025.101996_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40425-019-0641-x","article-title":"Oncolytic maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer","volume":"7","author":"McGray","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.101996_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OV.S154494","article-title":"Development and applications of oncolytic maraba virus vaccines","volume":"7","author":"Pol","year":"2018","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.smim.2025.101996_bib44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/2326-6066.CIR-17-0102","article-title":"Customized viral immunotherapy for HPV-Associated cancer","volume":"5","author":"Atherton","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2025.101996_bib45","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ijc.30813","article-title":"Oncolytic maraba virus MG1 as a treatment for sarcoma","volume":"141","author":"Le Boeuf","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib46","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/mt.2013.249","article-title":"Maraba virus as a potent oncolytic vaccine vector","volume":"22","author":"Pol","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib47","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/hep.32769","article-title":"Characterization of morreton virus as an oncolytic virotherapy platform for liver cancers","volume":"77","author":"Nagalo","year":"2023","journal-title":"Hepatol. Baltim. Md"},{"key":"10.1016\/j.smim.2025.101996_bib48","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib49","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1128\/JVI.02393-10","article-title":"Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo","volume":"85","author":"Cary","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101996_bib50","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1128\/JVI.01760-06","article-title":"Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, fas, and daxx","volume":"81","author":"Gaddy","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101996_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virol.2014.10.026","article-title":"Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus","volume":"474","author":"Felt","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.smim.2025.101996_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166538","article-title":"Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis","volume":"1868","author":"Lin","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.smim.2025.101996_bib53","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/1759-7714.14740","article-title":"RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus","volume":"14","author":"Zhang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/v17010016","article-title":"Employing the oncolytic vesicular stomatitis virus in cancer virotherapy: resistance and clinical considerations","volume":"17","author":"Abdelmageed","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2025.101996_bib55","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1016\/j.molcel.2021.07.040","article-title":"Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity","volume":"81","author":"Meng","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.smim.2025.101996_bib56","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41467-021-22115-1","article-title":"Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy","volume":"12","author":"Kottke","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105749","article-title":"Cellular resistance to an oncolytic virus is driven by chronic activation of innate immunity","volume":"26","author":"Larrieux","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.smim.2025.101996_bib58","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.omto.2021.11.013","article-title":"NEBL and AKT1 maybe new targets to eliminate the colorectal cancer cells resistance to oncolytic effect of vesicular stomatitis virus M-protein","volume":"23","author":"Mamizadeh","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.omto.2021.11.019","article-title":"Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus","volume":"24","author":"Goad","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib60","doi-asserted-by":"crossref","first-page":"5244","DOI":"10.3390\/ijms23095244","article-title":"Multiomic profiling identified EGF receptor signaling as a potential inhibitor of type I interferon response in models of oncolytic therapy by vesicular stomatitis virus","volume":"23","author":"Nikitina","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.smim.2025.101996_bib61","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1038\/s41467-024-48422-x","article-title":"Octyl itaconate enhances VSV\u039451 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways","volume":"15","author":"Kurmasheva","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib62","article-title":"4-octyl itaconate as a metabolite derivative inhibits inflammation via alkylation of STING","volume":"42","author":"Li","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2025.101996_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib64","doi-asserted-by":"crossref","unstructured":"J. Humeau, J. Le Naour, G. Kroemer, J.G. Pol, Immunogenic Cell Death in Cancer, in: Springer International Publishing, Cham, n.d.: pp. 1\u201361. \u3008https:\/\/doi.org\/10.1007\/16833_2022_121\u3009.","DOI":"10.1007\/16833_2022_121"},{"key":"10.1016\/j.smim.2025.101996_bib65","article-title":"Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity","volume":"32","author":"Hirigoyen","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib66","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.omto.2022.02.004","article-title":"Infection of non-cancer cells: a barrier or support for oncolytic virotherapy?","volume":"24","author":"Naumenko","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib67","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.4049\/jimmunol.1600106","article-title":"Privileged antigen presentation in splenic b cell follicles maximizes t cell responses in Prime-Boost vaccination","volume":"196","author":"Bridle","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib68","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1038\/s41467-024-54111-6","article-title":"VSV\u2206M51 drives CD8+ t cell-mediated tumour regression through infection of both cancer and non-cancer cells","volume":"15","author":"Rajwani","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/humc.2016.061","article-title":"Safety studies in tumor and Non-Tumor-Bearing mice in support of clinical trials using oncolytic VSV-IFN\u03b2-NIS","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.smim.2025.101996_bib70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41467-017-00324-x","article-title":"Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2018.06.001","article-title":"Visualizing oncolytic Virus-Host interactions in live mice using intravital microscopy","volume":"10","author":"Naumenko","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib72","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/mt.2011.26","article-title":"Targeting tumor vasculature with an oncolytic virus","volume":"19","author":"Breitbach","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101996_bib73","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1959140","article-title":"Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants","volume":"10","author":"Pipperger","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.101996_bib74","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.3390\/ijms21176347","article-title":"Characterization of the impact of oncolytic vesicular stomatitis virus on the trafficking, phenotype, and antigen presentation potential of neutrophils and their ability to acquire a Non-Structural viral protein","volume":"21","author":"Stegelmeier","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.smim.2025.101996_bib75","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-09-0334","article-title":"Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication","volume":"15","author":"Prestwich","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101996_bib76","article-title":"Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response","volume":"13","author":"Wu","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.smim.2025.101996_bib77","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/ijc.32325","article-title":"Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment","volume":"145","author":"Koske","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib78","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2025.101996_bib79","doi-asserted-by":"crossref","first-page":"374","DOI":"10.31083\/j.fbl2911374","article-title":"Oncolytic vesicular stomatitis virus: optimisation strategies for Anti-Cancer therapies","volume":"29","author":"Zinovieva","year":"2024","journal-title":"Front. Biosci. Landmark Ed."},{"key":"10.1016\/j.smim.2025.101996_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cytogfr.2020.10.007","article-title":"Cytokines in oncolytic virotherapy","volume":"56","author":"Pol","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.smim.2025.101996_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1503032","article-title":"Trial watch: oncolytic viro-immunotherapy of hematologic and solid tumors","volume":"7","author":"Pol","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.101996_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: oncolytic viruses make tumors \u201chot\u201d and suitable for checkpoint blockade immunotherapies","author":"Gujar","year":"2018","journal-title":"Oncoimmunology 7"},{"key":"10.1016\/j.smim.2025.101996_bib83","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.133.2.275","article-title":"ISOLATION OF a TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS","volume":"133","author":"Folkman","year":"1971","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2025.101996_bib84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00046361","article-title":"Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis","volume":"9","author":"Vlodavsky","year":"1990","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.smim.2025.101996_bib85","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","article-title":"Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma","volume":"69","author":"Willmon","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2025.101996_bib86","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1038\/ncomms6203","article-title":"Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER","volume":"5","author":"van den Beucken","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib87","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1128\/JVI.78.17.8960-8970.2004","article-title":"Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo","volume":"78","author":"Connor","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101996_bib88","article-title":"Mechanism of membrane fusion induced by vesicular stomatitis virus g protein","volume":"114","author":"Kim","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.smim.2025.101996_bib89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cytogfr.2020.07.007","article-title":"Tumour vasculature: friend or foe of oncolytic viruses?","volume":"56","author":"Santry","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.smim.2025.101996_bib90","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.101996_bib91","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.18632\/oncotarget.1942","article-title":"Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice","volume":"5","author":"Agrawal","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2025.101996_bib92","article-title":"Oncolytic virus-based hepatocellular carcinoma treatment: current status, intravenous delivery strategies, and emerging combination therapeutic solutions","volume":"18","author":"Li","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.smim.2025.101996_bib93","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14712598.2020.1787981","article-title":"A tool with many applications: vesicular stomatitis virus in research and Medicine","volume":"20","author":"Munis","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.smim.2025.101996_bib94","article-title":"Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we?","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12985-022-01757-7","article-title":"Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model","volume":"19","author":"Tang","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.smim.2025.101996_bib96","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.omto.2019.05.006","article-title":"Overexpression of smac by an armed vesicular stomatitis virus overcomes tumor resistance","volume":"14","author":"Li","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib97","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S1097-2765(00)00120-9","article-title":"Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98","volume":"6","author":"null von Kobbe","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.smim.2025.101996_bib98","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.cgt.7700794","article-title":"Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice","volume":"12","author":"Ebert","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib99","first-page":"1204","article-title":"Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer","volume":"7","author":"Zhao","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.smim.2025.101996_bib100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/hum.2021.048","article-title":"Antifibrotic therapy augments the antitumor effects of vesicular stomatitis virus via reprogramming tumor microenvironment","volume":"33","author":"Chen","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib101","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1158\/0008-5472.CAN-21-3656","article-title":"CDK4\/6 inhibition enhances oncolytic virus efficacy by potentiating Tumor-Selective cell killing and T-cell activation in refractory glioblastoma","volume":"82","author":"Xiao","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2025.101996_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032356","article-title":"Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines","volume":"13","author":"Alluqmani","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib103","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.omto.2022.04.004","article-title":"Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy","volume":"25","author":"Wong","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib104","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1158\/1078-0432.CCR-20-3365","article-title":"Mutations in the IFN\u03b3-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment","volume":"27","author":"Nguyen","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.smim.2025.101996_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1190669","article-title":"Construction of VSV\u039451M oncolytic virus expressing human interleukin-12","volume":"10","author":"Abdulal","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.smim.2025.101996_bib106","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.omto.2022.03.006","article-title":"IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor t cell activity","volume":"25","author":"El-Sayes","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003923","article-title":"Natural killer t cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression","volume":"10","author":"Nelson","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib108","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002096","article-title":"Natural killer t cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis","volume":"9","author":"Gebremeskel","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib109","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymthe.2017.10.014","article-title":"Multi-modal potentiation of oncolytic virotherapy by vanadium compounds","volume":"26","author":"Selman","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101996_bib110","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1016\/j.ymthe.2023.09.017","article-title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSV\u039451 oncolytic virotherapy","volume":"31","author":"Wong","year":"2023","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib111","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.995562","article-title":"Natural killer t cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice","volume":"4","author":"Gebremeskel","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.smim.2025.101996_bib112","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42003-020-0972-7","article-title":"The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy","volume":"3","author":"Arulanandam","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.smim.2025.101996_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1181014","article-title":"Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus","volume":"14","author":"Taha","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib114","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41392-024-02077-8","article-title":"Itaconate facilitates viral infection via alkylating GDI2 and retaining rab GTPase on the membrane","volume":"9","author":"Yin","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.smim.2025.101996_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1082191","article-title":"SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus","volume":"14","author":"Alkayyal","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib116","article-title":"Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models","volume":"33","author":"Daniel","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib117","article-title":"M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells","volume":"46","author":"G","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.smim.2025.101996_bib118","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.3748\/wjg.v20.i35.12493","article-title":"Current treatment options for colon cancer peritoneal carcinomatosis","volume":"20","author":"Aoyagi","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.smim.2025.101996_bib119","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jss.2019.07.032","article-title":"Immune effects of M51R vesicular stomatitis virus treatment of carcinomatosis from colon cancer","volume":"245","author":"Day","year":"2020","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.smim.2025.101996_bib120","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.virusres.2016.10.020","article-title":"Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers","volume":"228","author":"Fehl","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.smim.2025.101996_bib121","article-title":"M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells","volume":"46","author":"G","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.smim.2025.101996_bib122","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1128\/JVI.77.16.8843-8856.2003","article-title":"Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity","volume":"77","author":"Obuchi","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101996_bib123","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/icb.2012.7","article-title":"Modulation of T-cell function by type I interferon","volume":"90","author":"Tough","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.smim.2025.101996_bib124","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2025.101996_bib125","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2025.101996_bib126","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.4049\/jimmunol.176.4.2074","article-title":"Cutting edge: enhancement of antibody responses through direct stimulation of b and t cells by type I IFN","volume":"176","author":"Le Bon","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib127","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1172\/JCI37223","article-title":"Neutrophils responsive to endogenous IFN-\u03b2 regulate tumor angiogenesis and growth in a mouse tumor model","volume":"120","author":"Jablonska","year":"2010","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2025.101996_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2022.100247","article-title":"Discovery proteomics analysis determines that driver oncogenes suppress antiviral defense pathways through reduction in Interferon-\u03b2 autocrine stimulation","volume":"21","author":"Solomon","year":"2022","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"10.1016\/j.smim.2025.101996_bib129","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/mt.2011.65","article-title":"Thunder and lightning: immunotherapy and oncolytic viruses collide","volume":"19","author":"Melcher","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101996_bib130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR t cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2025.101996_bib131","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib132","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.omto.2023.05.006","article-title":"Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses","volume":"29","author":"Webb","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100736","article-title":"Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and May enhance long-term survivorship in dogs with naturally occurring osteosarcoma","volume":"31","author":"Makielski","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2018.08.003","article-title":"APOBEC3 mediates resistance to oncolytic viral therapy","volume":"11","author":"Huff","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib135","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","article-title":"APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity","volume":"5","author":"Swanton","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.smim.2025.101996_bib136","unstructured":"Vyriad, Inc., Phase 1-2 Trial of Systemically Administered VSV-IFN\u03b2-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors, clinicaltrials.gov, 2023. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03647163\u3009 (accessed March 29, 2023)."},{"key":"10.1016\/j.smim.2025.101996_bib137","series-title":"Cardio-Oncol","first-page":"1","article-title":"- current trends in cancer therapy","author":"Sekhon","year":"2017"},{"key":"10.1016\/j.smim.2025.101996_bib138","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1128\/JVI.02511-10","article-title":"Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism","volume":"85","author":"Muik","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101996_bib139","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41416-019-0574-7","article-title":"The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer","volume":"121","author":"Schreiber","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib140","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency","volume":"74","author":"Muik","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2025.101996_bib141","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.3390\/cancers13236107","article-title":"Heterologous Prime-Boost vaccination with a Peptide-Based vaccine and viral vector reshapes dendritic cell, CD4+ and CD8+ t cell phenotypes to improve the antitumor therapeutic effect","volume":"13","author":"Hofer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.smim.2025.101996_bib142","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/v10030108","article-title":"The oncolytic virus VSV-GP is effective against malignant melanoma","volume":"10","author":"Kimpel","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2025.101996_bib143","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/ijc.31556","article-title":"Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer","volume":"143","author":"Urbiola","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib144","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.21","article-title":"Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy","volume":"3","author":"Dold","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib145","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2022-0439","article-title":"Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors","volume":"18","author":"Porosnicu","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib146","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1038\/s41467-021-25506-6","article-title":"A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity","volume":"12","author":"Das","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib147","article-title":"Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer","volume":"32","author":"Geoffroy","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib148","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.omto.2023.02.009","article-title":"Multi-modal efficacy of a chimeric vesiculovirus expressing the morreton glycoprotein in sarcoma","volume":"29","author":"Watters","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib149","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fcimb.2018.00345","article-title":"Cellular and molecular immune response to chikungunya virus infection","volume":"8","author":"Tanabe","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.smim.2025.101996_bib150","unstructured":"Taxon Details | ICTV, (n.d.). \u3008https:\/\/ictv.global\/taxonomy\/taxondetails?taxnode_id=201901586\u3009 (accessed April 3, 2024)."},{"key":"10.1016\/j.smim.2025.101996_bib151","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01386-18","article-title":"A novel chimeric oncolytic virus vector for improved safety and efficacy as a platform for the treatment of hepatocellular carcinoma","volume":"92","author":"Abdullahi","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101996_bib152","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.3390\/cancers16193405","article-title":"A novel chimeric oncolytic virus mediates a multifaceted cellular immune response in a syngeneic B16 melanoma model","volume":"16","author":"Glau\u00df","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.smim.2025.101996_bib153","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/cancers13051044","article-title":"Adoptive t cell therapy is complemented by oncolytic virotherapy with fusogenic VSV-NDV in combination treatment of murine melanoma","volume":"13","author":"Krabbe","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.smim.2025.101996_bib154","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.omto.2023.08.001","article-title":"Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy","volume":"30","author":"Marek","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib155","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.omto.2020.08.007","article-title":"Oncolytic virus with attributes of vesicular stomatitis virus and measles virus in hepatobiliary and pancreatic cancers","volume":"18","author":"Nagalo","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib156","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virol.2020.10.009","article-title":"Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response","volume":"555","author":"van den Pol","year":"2021","journal-title":"Virology"},{"key":"10.1016\/j.smim.2025.101996_bib157","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1128\/JVI.00709-15","article-title":"Lassa-Vesicular stomatitis chimeric virus safely destroys brain tumors","volume":"89","author":"Wollmann","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101996_bib158","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omto.2021.06.003","article-title":"Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells","volume":"22","author":"Kim","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib159","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virol.2020.10.009","article-title":"Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response","volume":"555","author":"van den Pol","year":"2021","journal-title":"Virology"},{"key":"10.1016\/j.smim.2025.101996_bib160","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.3390\/v2122618","article-title":"Jaagsiekte sheep retrovirus biology and oncogenesis","volume":"2","author":"Hofacre","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2025.101996_bib161","doi-asserted-by":"crossref","DOI":"10.3171\/2020.11.FOCUS20839","article-title":"Inhibition of glioma using a novel non-neurotoxic vesicular stomatitis virus","volume":"50","author":"Jiang","year":"2021","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.smim.2025.101996_bib162","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00372-23","article-title":"Vesicular stomatitis virus (VSV) g glycoprotein can be modified to create a Her2\/Neu-Targeted VSV that eliminates large implanted mammary tumors","volume":"97","author":"Gao","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.101996_bib163","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor t cell response","volume":"15","author":"Webb","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168096","article-title":"Therapeutic efficacy of a VSV-GP-based human papilloma virus vaccine in a murine cancer model","volume":"435","author":"Riepler","year":"2023","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.smim.2025.101996_bib165","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.ymthe.2020.08.013","article-title":"Vesicular stomatitis virus encoding a destabilized tumor antigen improves activation of Anti-tumor t cell responses","volume":"28","author":"Huff","year":"2020","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib166","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94483-z","article-title":"Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis","volume":"11","author":"AuYeung","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2025.101996_bib167","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic viruses as Antigen-Agnostic cancer vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2025.101996_bib168","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1841392","article-title":"Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse","volume":"9","author":"Guo","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.101996_bib169","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib170","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000465","article-title":"Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality","volume":"8","author":"Niavarani","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib171","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nbt.2157","article-title":"Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma","volume":"30","author":"Pulido","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2025.101996_bib172","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41392-020-00364-8","article-title":"Cancer vaccines: shared tumor antigens return to the spotlight","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.smim.2025.101996_bib173","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib174","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006628","article-title":"Vaccinating against cancer: getting to prime time","volume":"11","author":"Chang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib175","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.3390\/cancers13236107","article-title":"Heterologous Prime-Boost vaccination with a Peptide-Based vaccine and viral vector reshapes dendritic cell, CD4+ and CD8+ t cell phenotypes to improve the antitumor therapeutic effect","volume":"13","author":"Hofer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.smim.2025.101996_bib176","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad030","article-title":"Cancer vaccines: from an immunology perspective","volume":"4","author":"Makker","year":"2024","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.smim.2025.101996_bib177","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/vaccines12090958","article-title":"An unconventional case study of neoadjuvant oncolytic virotherapy for recurrent breast cancer","volume":"12","author":"For\u010di\u0107","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.smim.2025.101996_bib178","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/d41586-024-03647-0","article-title":"This scientist treated her own cancer with viruses she grew in the lab","volume":"635","author":"Corbyn","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101996_bib179","unstructured":"Scientist treats her own breast cancer with viruses she grew in the lab. All you need to know about the treatment, Econ. Times (2024). \u3008https:\/\/economictimes.indiatimes.com\/news\/science\/scientist-beata-halassy-treats-her-own-breast-cancer-with-viruses-she-grew-in-the-lab-all-you-need-to-know-about-the-treatment-oncolytic-virotherapy\/articleshow\/115255138.cms?from=mdr\u3009 (accessed January 24, 2025)."},{"key":"10.1016\/j.smim.2025.101996_bib180","unstructured":"P. Hsieh, A Scientist Cured Her Breast Cancer With Self-Experimentation, But Multiple Journals Rejected Her Paper, Forbes (n.d.). \u3008https:\/\/www.forbes.com\/sites\/paulhsieh\/2024\/11\/30\/a-scientist-cured-her-breast-cancer-with-self-experimentation-but-multiple-journals-rejected-her-paper\/\u3009 (accessed January 24, 2025)."},{"key":"10.1016\/j.smim.2025.101996_bib181","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00873","article-title":"The role of interferons in inflammation and inflammasome activation","volume":"8","author":"Kopitar-Jerala","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib182","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ymthe.2003.12.004","article-title":"Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus","volume":"9","author":"Shinozaki","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101996_bib183","unstructured":"Mayo Clinic, 2022, Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III\/IV Cutaneous Melanoma, clinicaltrials.gov, 2022\u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03865212\u3009(accessed April 10, 2023).."},{"key":"10.1016\/j.smim.2025.101996_bib184","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2011.451","article-title":"TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome","volume":"105","author":"Journe","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14740338.2022.1993819","article-title":"Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma","volume":"21","author":"Villani","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.smim.2025.101996_bib186","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10238-024-01546-2","article-title":"Beyond checkpoint inhibitors: the three generations of immunotherapy","volume":"25","author":"Schaub","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.smim.2025.101996_bib187","unstructured":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer - Tabular View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03120624\u3009 (accessed March 30, 2023)."},{"key":"10.1016\/j.smim.2025.101996_bib188","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fonc.2016.00142","article-title":"Rationally repurposing ruxolitinib (Jakafi (\u00ae)) as a Solid Tumor Therapeutic","volume":"6","author":"Tavallai","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib189","unstructured":"Mayo Clinic, 2023, Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic\/Dendritic Cell Neoplasms, clinicaltrials.gov, 2023\u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03017820\u3009(accessed April 9, 2023).."},{"key":"10.1016\/j.smim.2025.101996_bib190","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"Sistigu","year":"2011","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.smim.2025.101996_bib191","unstructured":"Immune Checkpoint Inhibitors and Their Side Effects, (n.d.). \u3008https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/treatment-types\/immunotherapy\/immune-checkpoint-inhibitors.html\u3009 (accessed April 11, 2023)."},{"key":"10.1016\/j.smim.2025.101996_bib192","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2021.39.15_suppl.2500","article-title":"Clinical activity of systemic VSV-IFN\u03b2-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"39","author":"Cook","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib193","unstructured":"Boehringer Ingelheim, Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With Ezabenlimab in Patients With Advanced or Metastatic Solid Tumors, clinicaltrials.gov, 2023. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05155332\u3009 (accessed March 23, 2023)."},{"key":"10.1016\/j.smim.2025.101996_bib194","article-title":"137P First-in-human results from a phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors","volume":"20","author":"Champiat","year":"2023","journal-title":"ImmunoOncol. Technol."},{"key":"10.1016\/j.smim.2025.101996_bib195","unstructured":"Amal TherapeuticsA Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150\/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients With KRAS G12D\/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02), clinicaltrials.gov2023, \u3008https:\/\/clinicaltrials.gov\/study\/NCT05846516\u3009(accessed January 1, 2023).."},{"key":"10.1016\/j.smim.2025.101996_bib196","unstructured":"KRAS KRAS proto-oncogene, GTPase [Homo sapiens (human)] - Gene - NCBI, (n.d.). \u3008https:\/\/www.ncbi.nlm.nih.gov\/gene\/3845\u3009 (accessed February 8, 2024)."},{"key":"10.1016\/j.smim.2025.101996_bib197","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3390\/cells11193175","article-title":"KRAS G12D mutation subtype in pancreatic ductal adenocarcinoma: does it influence prognosis or stage of disease at presentation?","volume":"11","author":"Shen","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.smim.2025.101996_bib198","unstructured":"B. Ingelheim, NCT04046445 (KISIMA-01), InOncology (2022). \u3008https:\/\/pro.boehringer-ingelheim.com\/inoncology\/our-pipeline\/ezabenlimab\/nct04046445-KISIMA-01\u3009 (accessed April 11, 2023)."},{"key":"10.1016\/j.smim.2025.101996_bib199","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011517","article-title":"North China petroleum bureau general hospital, phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors","volume":"13","author":"Hua","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib200","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/mt.2012.204","article-title":"The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice","volume":"21","author":"Rommelfanger","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.smim.2025.101996_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1279387","article-title":"A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and t cell responses","volume":"14","author":"Smith","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101996_bib202","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41467-020-14568-7","article-title":"APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy","volume":"11","author":"Driscoll","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101996_bib203","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.21873\/anticanres.16264","article-title":"Oncolytic effect of a recombinant vesicular stomatitis virus encoding a Tumor-suppressor MicroRNA in an osteosarcoma mouse model","volume":"43","author":"Sakuda","year":"2023","journal-title":"Anticancer Res."},{"key":"10.1016\/j.smim.2025.101996_bib204","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2018.12.001","article-title":"Enhanced safety and efficacy of oncolytic VSV therapy by combination with t cell receptor transgenic t cells as carriers","volume":"12","author":"Melzer","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101996_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100782","article-title":"Blood outgrowth endothelial cells as a cellular carrier for oncolytic vesicular stomatitis virus expressing Interferon-\u03b2 in preclinical models of Non-Small cell lung cancer","volume":"13","author":"Patel","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib206","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7150\/thno.10438","article-title":"Characterization of magnetic viral complexes for targeted delivery in oncology","volume":"5","author":"Almst\u00e4tter","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.smim.2025.101996_bib207","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.101996_bib208","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101996_bib209","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2022-0439","article-title":"Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors","volume":"18","author":"Porosnicu","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.smim.2025.101996_bib210","doi-asserted-by":"crossref","first-page":"CT072","DOI":"10.1158\/1538-7445.AM2018-CT072","article-title":"Abstract CT072: first in human (FIH) dose escalation studies of intravenous administration of VSV-IFN\u03b2-NIS (Voyager-V1\u2122) in stage IV or recurrent endometrial cancer","volume":"78","author":"Bakkum-Gamez","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2025.101996_bib211","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.1200\/JCO.2023.41.16_suppl.7530","article-title":"Systemic VSV-IFN\u03b2-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"41","author":"Bennani","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:41:00Z","timestamp":1778582460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532325000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":210,"alternative-id":["S1044532325000685"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.101996","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latest insights into oncolytic viro-immunotherapy with vesicular stomatitis virus","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.101996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101996"}}